BRAF mutations in CRC are associated with poor prognosis as patients tend to have more aggressive disease, advanced stages at diagnosis, higher likelihood of lymph node involvement, and lower overall survival rates compared to patients with BRAF wild-type tumors [316]. The gene discussed is BRAF; the disease is colorectal carcinoma.